Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 9, 2015, Pages 934-942

  Swanson, Sonja A ^a   Hernandez Diaz, Sonia ^a   Palmsten, Kristin ^b   Mogun, Helen ^c   Olfson, Mark ^d   Huybrechts, Krista F ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Surgeons of Columbia University ^*  (United States)

Author keywords

Administrative data; Antidepressant; Confounding; Effectiveness; Pharmacoepidemiolgy; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOMUTILATION; CHILD; COMORBIDITY; DEPRESSION; FEMALE; HOSPITALIZATION; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL WELFARE; MEDICAID; MENSTRUAL CYCLE; MENTAL HEALTH; PREGNANCY; PRIORITY JOURNAL; PROPENSITY SCORE; COHORT ANALYSIS; PREGNANCY COMPLICATIONS; PROCEDURES; STATISTICS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSION; FEMALE; HUMANS; MEDICAID; PREGNANCY; PREGNANCY COMPLICATIONS; PROPENSITY SCORE; STATISTICS AS TOPIC; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84940959008     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3798     Document Type: Article

References (36)

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol Jun 2007; 196(6):544 e541-e545.
2. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol Feb 2008; 198(2): 194 e191-e195.
3. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry May-Jun 2013; 35(3): 265-271.
4. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. Mar 2010; 88(3): 159-170.
5. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernandez-Diaz S. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?. Am J Epidemiol May 15 2012; 175(10): 988-997.
6. Yonkers KA, Norwitz ER, Smith MV, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology Sep 2012; 23(5): 677-685.
7. Palmsten K, Hernandez-Diaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013; 347: f4877.
8. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med Jun 19 2014; 370(25): 2397-2407.
9. Walker AM. Confounding by indication. Epidemiology Jul 1996; 7(4): 335-336.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41-55.
11. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (Cambridge, Mass.) 2009; 20(4): 512-522.
12. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91(434): 444-455.
13. Hernan MA, Robins JM. Instruments for causal inference: an epidemiologist's dream?. Epidemiology Jul 2006; 17(4): 360-372.
14. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Community Stat 1994; 23: 2379-2412.
15. Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernan MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res Feb 2013; 22(1): 70-96.
16. Collaboration H-C, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Aids Jan 2 2010; 24(1): 123-137.
17. Palmsten K, Huybrechts KF, Mogun H, et al. Harnessing the medicaid analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One 2013; 8(6): e67405.
18. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernandez-Diaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf Jan 2013; 22(1): 16-24.
19. Miller M, Pate V, Swanson SA, Azrael D, White A, Sturmer T. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA. CNS Drugs Jan 2014; 28(1): 79-88.
20. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA Jun 18 2003; 289(23): 3095-3105.
21. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA Jan 6 2010; 303(1): 47-53.
22. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. Feb 1 2006; 295(5): 499-507.
23. Miller M, Swanson SA, Azrael D, Pate V, Sturmer T. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Jun 2014; 174(6): 899-909.
24. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology Jul 2009; 20(4): 512-522.
25. Bound J, Jaeger D, Baker R. Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. J Am Stat Assoc 1995; 90(430): 443-450.
26. Jackson J, Swanson SA. Toward a clearer portrayal of confounding bias in instrumental variable analyses. Epidemiology (Cambridge, Mass.). in press.
27. Swanson SA, Hernan MA. Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology May 2013; 24(3): 370-374.
28. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. The Int J biostatistics 2007; 3(1): Article 14.
29. Chen Y, Briesacher BA. Use of instrumental variable in prescription drug research with observational data: a systematic review. J Clin Epidemiol Jun 2011; 64(6): 687-700.
30. Davies NM, Smith GD, Windmeijer F, Martin RM. Issues in the reporting and conduct of instrumental variable studies: a systematic review. Epidemiology May 2013; 24(3): 363-369.
31. Palmsten K, Hernandez-Diaz S. Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs?. Epidemiology Sep 2012; 23(5): 686-688.
32. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy?. Epidemiology Nov 2011; 22(6): 848-854.
33. Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry Nov 2011; 72(11): e1563-e1569.
34. Sit D, Perel JM, Luther JF, Wisniewski SR, Helsel JC, Wisner KL. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol Aug 2010; 30(4): 381-386.
35. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67(Suppl 4): 27-30.
36. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880.